Fund moves
58 tracked managers disclosed the same change for Q4 2025. From a 13F filed Jan 30, 2026 covering holdings at Dec 31, 2025 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Jan 6, 2026 · Filed Jan 6, 2026
Edwards Lifesciences's CVP,Strategy/Corp Development sold $749K of Edwards Lifesciences shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$748,708
Shares × reported transaction price
68 days after results of Oct 30, 2025, 35 days before results of Feb 10, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $85.85 on Jan 6, 2026, within 2% of its 52-week high, after a 2% rise over the previous 30 trading days
52-week range $67.07 (Apr 8, 2025) to $86.94 (Dec 29, 2025), 95% of the way up, from 250 adjusted closes. 30 trading days earlier: $84.09 on Nov 20, 2025. Describes the past only, not a forecast
RSI 54, 10% above its 200-day average, 2% above its 50-day average, 1% below the 52-week high, 20-day volatility 18% a year, against the S&P 500: −1 points over 1 month, +9 points over 3 months, +1 points over 6 months
From the adjusted closes up to Jan 6, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
A securities lawsuit naming the company as a defendant was filed on Oct 14, 2024 in the U.S. District Court, C.D. California. A filing is an allegation, not a finding.
Dhimant Patel v. Edwards Lifesciences Corporation, docket 8:24-cv-02221, via CourtListener (court records). Nature of suit 850, company named as first defendant
FDA approved SAPIEN M3 Transcatheter Mitral Valve Replacement System on Dec 22, 2025, 15 days before this trade.
Premarket approval (PMA): Prosthesis, mitral valve, percutaneously delivered. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −2.0% | +0.1% | −2.1% |
| 30 days | −7.2% | +0.1% | −7.4% |
| 90 days | −4.7% | −4.4% | −0.3% |
| 180 days | +12.2% | +8.9% | +3.3% |
Past results only. Not a forecast.
Fund moves
58 tracked managers disclosed the same change for Q4 2025. From a 13F filed Jan 30, 2026 covering holdings at Dec 31, 2025 — a quarter-end snapshot, not a live trade.
Fund moves
58 tracked managers disclosed the same change for Q4 2025. From a 13F filed Jan 27, 2026 covering holdings at Dec 31, 2025 — a quarter-end snapshot, not a live trade.
Fund moves
54 tracked managers disclosed the same change for Q4 2025. From a 13F filed Jan 22, 2026 covering holdings at Dec 31, 2025 — a quarter-end snapshot, not a live trade.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.